Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria

Lancet

Volumn 358, Issue 9285, 2001, Pages 890-891

  Djimdé, Abdoulaye ^a,b,d   Doumbo, Ogobara K ^a   Steketee, Richard W ^c   Plowe, Christopher V ^d  

^a UNIVERSITY OF BAMAKO   (Mali)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FOLIC ACID ANTAGONIST;

AFRICA; ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; ENDEMIC DISEASE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; MALARIA FALCIPARUM; MARKER GENE; PLASMODIUM FALCIPARUM; POINT MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035883813     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06040-8     Document Type: Article

References (5)

1. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa
2. Mutations in the P falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
3. A molecular marker for chloroquine-resistant falciparum malaria
4. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: Parasitological resistance vs therapeutic efficacy
5. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance